External	0	8	O
beam	9	13	O
radiotherapy	14	26	O
for	27	30	O
subretinal	31	41	O
neovascularization	42	60	O
in	61	63	O
age	64	67	O
-	67	68	O
related	68	75	O
macular	76	83	B-Tissue
degeneration	84	96	O
:	96	97	O
is	98	100	O
this	101	105	O
treatment	106	115	O
efficient	116	125	O
?	125	126	O

PURPOSE	128	135	O
:	135	136	O
Control	137	144	O
of	145	147	O
the	148	151	O
natural	152	159	O
course	160	166	O
of	167	169	O
subretinal	170	180	O
neovascularization	181	199	O
(	200	201	O
SRNV	201	205	O
)	205	206	O
in	207	209	O
age	210	213	O
-	213	214	O
related	214	221	O
macular	222	229	B-Tissue
degeneration	230	242	O
(	243	244	O
AMD	244	247	O
)	247	248	O
is	249	251	O
difficult	252	261	O
.	261	262	O

Only	263	267	O
a	268	269	O
subset	270	276	O
of	277	279	O
patients	280	288	B-Organism
is	289	291	O
suitable	292	300	O
for	301	304	O
laser	305	310	O
coagulation	311	322	O
.	322	323	O

This	324	328	O
prospective	329	340	O
study	341	346	O
aimed	347	352	O
to	353	355	O
determine	356	365	O
the	366	369	O
efficacy	370	378	O
and	379	382	O
individual	383	393	O
benefit	394	401	O
of	402	404	O
external	405	413	O
beam	414	418	O
radiotherapy	419	431	O
(	432	433	O
EBRT	433	437	O
)	437	438	O
.	438	439	O

METHODS	440	447	O
AND	448	451	O
MATERIALS	452	461	O
:	461	462	O
The	463	466	O
prospective	467	478	O
trial	479	484	O
included	485	493	O
287	494	497	O
patients	498	506	B-Organism
with	507	511	O
subfoveal	512	521	O
neovascularization	522	540	O
due	541	544	O
to	545	547	O
AMD	548	551	O
which	552	557	O
was	558	561	O
verified	562	570	O
by	571	573	O
fluorescein	574	585	B-Drug_or_compound
angiography	586	597	O
.	597	598	O

Patients	599	607	B-Organism
have	608	612	O
been	613	617	O
treated	618	625	O
between	626	633	O
January	634	641	O
1996	642	646	O
and	647	650	O
October	651	658	O
1997	659	663	O
.	663	664	O

All	665	668	O
patients	669	677	B-Organism
received	678	686	O
a	687	688	O
total	689	694	O
dose	695	699	O
of	700	702	O
16	703	705	O
Gy	706	708	O
in	709	711	O
2	712	713	O
-	713	714	O
Gy	714	716	O
daily	717	722	O
fractions	723	732	O
with	733	737	O
5	738	739	O
-	739	740	O
6	740	741	O
MeV	742	745	O
photons	746	753	O
based	754	759	O
on	760	762	O
computerized	763	775	O
treatment	776	785	O
planning	786	794	O
in	795	797	O
individual	798	808	O
head	809	813	B-Organism_subdivision
mask	814	818	O
fixation	819	827	O
.	827	828	O

This	829	833	O
first	834	839	O
analysis	840	848	O
is	849	851	O
based	852	857	O
on	858	860	O
73	861	863	O
patients	864	872	B-Organism
(	873	874	O
50	874	876	O
women	877	882	B-Organism
,	882	883	O
23	884	886	O
men	887	890	B-Organism
,	890	891	O
median	892	898	O
age	899	902	O
74	903	905	O
.	905	906	O
3	906	907	O
years	908	913	O
)	913	914	O
,	914	915	O
with	916	920	O
a	921	922	O
median	923	929	O
follow	930	936	O
-	936	937	O
up	937	939	O
of	940	942	O
13	943	945	O
.	945	946	O
3	946	947	O
months	948	954	O
and	955	958	O
a	959	960	O
minimum	961	968	O
follow	969	975	O
-	975	976	O
up	976	978	O
of	979	981	O
11	982	984	O
months	985	991	O
.	991	992	O

RESULTS	993	1000	O
:	1000	1001	O
All	1002	1005	O
patients	1006	1014	B-Organism
completed	1015	1024	O
therapy	1025	1032	O
and	1033	1036	O
tolerability	1037	1049	O
was	1050	1053	O
good	1054	1058	O
.	1058	1059	O

First	1060	1065	O
clinical	1066	1074	O
control	1075	1082	O
with	1083	1087	O
second	1088	1094	O
angiography	1095	1106	O
was	1107	1110	O
performed	1111	1120	O
6	1121	1122	O
weeks	1123	1128	O
after	1129	1134	O
irradiation	1135	1146	O
,	1146	1147	O
then	1148	1152	O
in	1153	1155	O
3	1156	1157	O
-	1157	1158	O
month	1158	1163	O
intervals	1164	1173	O
.	1173	1174	O

Eighteen	1175	1183	O
patients	1184	1192	B-Organism
with	1193	1197	O
SRNV	1198	1202	O
refusing	1203	1211	O
radiotherapy	1212	1224	O
served	1225	1231	O
as	1232	1234	O
a	1235	1236	O
control	1237	1244	O
group	1245	1250	O
and	1251	1254	O
were	1255	1259	O
matched	1260	1267	O
with	1268	1272	O
18	1273	1275	O
irradiated	1276	1286	O
patients	1287	1295	B-Organism
.	1295	1296	O

After	1297	1302	O
7	1303	1304	O
months	1305	1311	O
median	1312	1318	O
visual	1319	1325	O
acuity	1326	1332	O
(	1333	1334	O
VA	1334	1336	O
)	1336	1337	O
was	1338	1341	O
20	1342	1344	O
/	1344	1345	O
160	1345	1348	O
for	1349	1352	O
the	1353	1356	O
irradiated	1357	1367	O
and	1368	1371	O
20	1372	1374	O
/	1374	1375	O
400	1375	1378	O
for	1379	1382	O
the	1383	1386	O
untreated	1387	1396	O
patients	1397	1405	B-Organism
.	1405	1406	O

One	1407	1410	O
year	1411	1415	O
after	1416	1421	O
radiotherapy	1422	1434	O
final	1435	1440	O
median	1441	1447	O
VA	1448	1450	O
was	1451	1454	O
20	1455	1457	O
/	1457	1458	O
400	1458	1461	O
in	1462	1464	O
both	1465	1469	O
groups	1470	1476	O
.	1476	1477	O

CONCLUSION	1478	1488	O
:	1488	1489	O
These	1490	1495	O
results	1496	1503	O
suggest	1504	1511	O
that	1512	1516	O
16	1517	1519	O
Gy	1520	1522	O
of	1523	1525	O
conventionally	1526	1540	O
fractionated	1541	1553	O
external	1554	1562	O
beam	1563	1567	O
irradiation	1568	1579	O
slows	1580	1585	O
down	1586	1590	O
the	1591	1594	O
visual	1595	1601	O
loss	1602	1606	O
in	1607	1609	O
exudative	1610	1619	O
AMD	1620	1623	O
for	1624	1627	O
only	1628	1632	O
a	1633	1634	O
few	1635	1638	O
months	1639	1645	O
.	1645	1646	O

Patients	1647	1655	B-Organism
'	1655	1656	O
reading	1657	1664	O
vision	1665	1671	O
could	1672	1677	O
not	1678	1681	O
be	1682	1684	O
saved	1685	1690	O
for	1691	1694	O
a	1695	1696	O
long	1697	1701	O
-	1701	1702	O
term	1702	1706	O
run	1707	1710	O
.	1710	1711	O

